{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T08:27:13Z","timestamp":1790497633483,"version":"4.1.0"},"reference-count":13,"publisher":"eLife Sciences Publications, Ltd","license":[{"start":{"date-parts":[[2019,1,30]],"date-time":"2019-01-30T00:00:00Z","timestamp":1548806400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,1,30]],"date-time":"2019-01-30T00:00:00Z","timestamp":1548806400000},"content-version":"am","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,1,30]],"date-time":"2019-01-30T00:00:00Z","timestamp":1548806400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elifesciences.org"],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:p>We are writing to communicate our concerns regarding the recently published study by Lees-Shepard et al. (2018).<\/jats:p>","DOI":"10.7554\/elife.43173","type":"journal-article","created":{"date-parts":[[2019,1,30]],"date-time":"2019-01-30T09:00:17Z","timestamp":1548838817000},"update-policy":"https:\/\/doi.org\/10.7554\/elife.43173","source":"Crossref","is-referenced-by-count":3,"title":["Comment on 'Palovarotene reduces heterotopic ossification in juvenile FOP mice but exhibits pronounced skeletal toxicity'"],"prefix":"10.7554","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6854-4942","authenticated-orcid":true,"given":"Maurizio","family":"Pacifici","sequence":"first","affiliation":[{"name":"Translational Research Program in Pediatric Orthopaedics, The Children's Hospital of Philadelphia, Philadelphia, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2609-6971","authenticated-orcid":true,"given":"Eileen M","family":"Shore","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, University of Pennsylvania, Philadelphia, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4374","published-online":{"date-parts":[[2019,1,30]]},"reference":[{"key":"bib1","first-page":"229","volume-title":"The Retinoids: Biology, Chemistry, and Medicine","author":"Blaner","year":"1994"},{"key":"bib2","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1002\/jbmr.2820","article-title":"Palovarotene inhibits heterotopic ossification and maintains limb mobility and growth in mice with the human ACVR1(R206H) Fibrodysplasia ossificans progressiva (FOP) mutation","volume":"31","author":"Chakkalakal","year":"2016","journal-title":"Journal of Bone and Mineral Research"},{"key":"bib3","doi-asserted-by":"publisher","first-page":"14971","DOI":"10.1074\/jbc.271.25.14971","article-title":"An analysis of retinoic acid-induced gene expression and metabolism in AB1 embryonic stem cells","volume":"271","author":"Chen","year":"1996","journal-title":"Journal of Biological Chemistry"},{"key":"bib4","article-title":"Clementia announces updated phase 2 part B data on palovarotene for FOP","volume-title":"Globe Newswire","author":"Clementia Pharmaceuticals","year":"2018","unstructured":"Clementia Pharmaceuticals. 2018. Clementia announces updated phase 2 part B data on palovarotene for FOP. Globe Newswire. https:\/\/globenewswire.com\/news-release\/2018\/09\/26\/1576476\/0\/en\/Clementia-Announces-Updated-Phase-2-Part-B-Data-on-Palovarotene-for-FOP.html [Accessed December 9, 2018]."},{"key":"bib5","doi-asserted-by":"crossref","first-page":"10590","DOI":"10.1016\/S0021-9258(19)85126-8","article-title":"Metabolism of all-trans-retinoic acid and all-trans-retinyl acetate. Demonstration of common physiological metabolites in rat small intestinal mucosa and circulation","volume":"260","author":"Cullum","year":"1985","journal-title":"The Journal of Biological Chemistry"},{"key":"bib6","volume-title":"Casarett and Doull's Toxicology: The Basic Science of Poisons","author":"Eaton","year":"2013"},{"key":"bib7","doi-asserted-by":"publisher","first-page":"4013","DOI":"10.1128\/MCB.23.11.4013-4025.2003","article-title":"Evolutionary divergence of platelet-derived growth factor alpha receptor signaling mechanisms","volume":"23","author":"Hamilton","year":"2003","journal-title":"Molecular and Cellular Biology"},{"key":"bib8","first-page":"1243","article-title":"Palovarotene, a novel retinoic acid receptor gamma agonist for the treatment of emphysema","volume":"10","author":"Hind","year":"2009","journal-title":"Current Opinion in Investigational Drugs"},{"key":"bib9","doi-asserted-by":"publisher","first-page":"17850","DOI":"10.1074\/jbc.270.30.17850","article-title":"Plasma delivery of retinoic acid to tissues in the rat","volume":"270","author":"Kurlandsky","year":"1995","journal-title":"Journal of Biological Chemistry"},{"key":"bib10","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.40814","article-title":"Palovarotene reduces heterotopic ossification in juvenile FOP mice but exhibits pronounced skeletal toxicity","volume":"7","author":"Lees-Shepard","year":"2018","journal-title":"eLife"},{"key":"bib11","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/S0022-2275(20)37420-4","article-title":"Metabolism of all-trans-retinoic acid by cultured human epidermal keratinocytes","volume":"38","author":"Randolph","year":"1997","journal-title":"Journal of Lipid Research"},{"key":"bib12","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1038\/nm.2334","article-title":"Potent inhibition of heterotopic ossification by nuclear retinoic acid receptor-\u03b3 agonists","volume":"17","author":"Shimono","year":"2011","journal-title":"Nature Medicine"},{"key":"bib13","first-page":"47","article-title":"Hypervitaminosis A in young ducks: The epiphyseal cartilage","volume":"55","author":"Wolbach","year":"1953","journal-title":"Archives of Pathology"}],"container-title":["eLife"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/cdn.elifesciences.org\/articles\/43173\/elife-43173-v1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/cdn.elifesciences.org\/articles\/43173\/elife-43173-v1.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/elifesciences.org\/articles\/43173","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T00:53:33Z","timestamp":1697072013000},"score":1,"resource":{"primary":{"URL":"https:\/\/elifesciences.org\/articles\/43173"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,30]]},"references-count":13,"alternative-id":["10.7554\/eLife.43173"],"URL":"https:\/\/doi.org\/10.7554\/elife.43173","archive":["CLOCKSS"],"relation":{},"ISSN":["2050-084X"],"issn-type":[{"value":"2050-084X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,30]]},"article-number":"e43173"}}